Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2004

View Archived Issues

ON-1910Na effective against human liver cancer in vivo

Novel iNOS inhibitor against inflammation

KS-119, a potential hypoxic cell cytotoxin

Palmitoyl-CoA oxidation inhibitor analogues for inducing metabolic shift

Novel camptothecin derivatives with enhanced stability and antitumor activity

Access' AP-5346 shows greater Pt delivery to tumor DNA than oxaliplatin

Phytobiotech changes name to Avance Pharma

Review of phase II Propofol IDD-D results completed

Financing at Favrille supports phase II and phase III trials

Targeted Genetics and Elan conclude Emerald Gene Systems joint venture

Eisai to promote Imurek in Germany

Inflazyme to acquire Adprotech

KV Pharmaceutical and Arrow sign marketing deal for Gynazole-1

Factor 5A1 induces apoptosis in lung cancer mice study

INGN-241 enters phase II trial in metastatic melanoma

European approval sought for candesartan cilexetil for chronic heart failure

Novartis to license calcitonin technology from Unigene

Extina NDA accepted for filing

Genta presents new data on the antitumor effects of oblimersen sodium and gallium nitrate

Micellar paclitaxel improves symptoms of severe psoriasis

CXCR2 receptor antagonists claimed in AstraZeneca patent

Novel modulators of chemokine CCR5 receptor activity identified by AstraZeneca

Bayer patents PDE9 inhibitors for improving learning, memory and concentration

Benzoyl piperidine compounds for CNS disorders

GSK claims new potent and selective COX-2 inhibitors for pain, inflammation, etc.

Dual serotonin reuptake inhibitors/alpha2-adrenoceptor antagonists emerge from Janssen research

Topical tacrolimus reported effective in a mild case of vesicular pemphigoid

Novel optimized antimalarial artemisinin analogues

Melanin-concentrating hormone receptor antagonist against obesity

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...